New analysis from Silexion's Phase 2 trial of LODER shows a 56% objective response rate (ORR) and 67% resectability improvement in non-resectable pancreatic cancer GRAND CAYMAN, Cayman ...

Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.

Detailed price information for Silexion Therapeutics Corp (SLXN-Q) from The Globe and Mail including charting and trades.

LONDON--(BUSINESS WIRE)--Silexion Therapeutics (NASDAQ: SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference ...

Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven ...

GRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA ...

Erratum: Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study The article by Fietkau et al entitled “Benefit ...

Pancreatic cancer treatment relies on surgery, chemotherapy, and radiation, with surgery for non-metastatic, technically resectable tumors. Advances in chemotherapy, neoadjuvant approaches, and ...

Pancreatic cancer is mostly pancreatic ductal adenocarcinoma, with late-stage detection due to non-specific symptoms like jaundice and abdominal pain. Diagnosis involves imaging tests, biopsies, and ...